透雲生物(01332.HK):萊茵衣藻項目兩台18萬升發酵罐連續發酵生產試車成功
格隆匯12月28日丨透雲生物(01332.HK)公吿,根據最新發展及截至2021年12月28日,萊茵衣藻項目兩台18萬升發酵罐連續發酵生產試車成功。所有電氣、自控設備運作正常,產品合格,標誌本集團萊茵衣藻項目正式投產。其餘六台18萬升發酵罐將陸續投產,預計2022年下半年全部達產,達產後的萊茵衣藻年產量為4,000噸。第二期年產量6,000噸的廠房及設備等設計已開始,2022下半年視市場情況動工建設。
由於人們越來越注重健康,本公司董事會認為萊茵衣藻及微藻產品市場具有增長潛力。萊茵衣藻正式投產後,生產及銷售萊茵衣藻及微藻相關產品將有助多元化本集團業務及擴大其收入來源。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.